Diagnosis of Latent Tuberculosis in Patients with Systemic Lupus Erythematosus: T.SPOT.TB versus Tuberculin Skin Test

Table 6

T.SPOT.TB indeterminate versus T.SPOT.TB determinate results. Univariate analyses.

Clinical and laboratory findings	Indeterminate T.SPOT.TB (𝑛=4)	Determinate T.SPOT.TB (𝑛=88)	𝑃 value
Age, years, mean ± SD	55.50±13.17	42.13±14.76	0.079
Patients with risk factors for LTBI, 𝑛 (%)	1 (25)	8 (9)	0.34
SLE disease duration, median (IQR)	318 (117–351)	138 (60–207)	0.028
SLEDAI, mean ± SD	2.25±1.25	3.38±2.78	0.42
SLICC, median (IQR)	1 (1–1.75)	0 (0-1)	0.002
dsDNAn, UI/mL, median	13.5 (6.77–332.75)	14.50 (3.72–43.50)	0.85
Prednisone > 7.5 mg/d, 𝑛 (%)	0 (0)	18 (33.3)	0.31
Immunosuppressed patients, 𝑛 (%)	3 (75)	56 (63.6)	0.64
Hydroxychloroquine treatment, 𝑛 (%)	2 (50)	77 (87.5)	0.94
Steroid dosage, mg, mean ± SD	2.62±2.05	3.94±4.93	0.59
Steroid cumulative dose, mg, mean ± SD	35745.62±27062.79	17117.40±21498.45	0.09
Steroid cumulative dose/disease duration, mg/year, mean ± SD	1766.47±1248.49	1598.69±1451.84	0.82
Mycophenolate dose, mg, mean ± SD	0	261.47±533.49	0.001
Mycophenolate cumulative dose, mg, mean ± SD	0	629112.50±1317998.72	0.001
Mycophenolate cumulative dose/disease duration, mg/year, mean ± SD	0	75237.27±159546.95	0.001
Methotrexate dose, mg, mean ± SD	1.25±2.5	1.22±3.28	0.98
Methotrexate cumulative dose, mg, mean ± SD	150±300	322.50±793.78	0.66
Cumulative methotrexate dose/disease duration, mg/year, mean ± SD	13.63±27.27	47.61±131.30	0.60